International Journal of Innovative Research in Computer Science and Technology (IJIRCST)
ISSN (Online): 2347-5552, Volume-13, Issue-3, May 2025
https:/doi.org/10.55524/ijircst.2025.13.3.13
Article ID IJIRE-1402, Pages 76-81
www.ijircst.org

AI-Based Predictive Tools for Managing and Preventing Cardiovascular Diseases

Saad Rasool[1], Abdullah Mazharuddin Khaja[2], Yawar Hayat[3], and Arbaz Haider Khan[4]

[1]AI Healthcare Researcher, Department of Computer Science and Engineering , American National University, Virginia, USA
[2]MS Scholar, Computer Science, Governors State university, University Park, IL, USA
[3]AI Healthcare Researcher, Institute of Business Administration, Karachi, Pakistan
[4]AI Healthcare Researcher, Department Of Computer Science, University Of Engineering And Technology, Lahore, Pakistan

Correspondence should be addressed to Saad Rasool; saadrasool6@gmail.com

Received 13 April 2025; Revised 26 April 2025; Accepted 11 May 2025

ABSTRACT- A large percentage of deaths each year are caused by cardiovascular diseases (CVDs), which are a serious worldwide health concern. Particularly in varied groups with complicated risk profiles, the predictive value of current risk assessment techniques, such the Framingham Risk Score, is limited. In this work, we investigate how ML techniques can improve the prediction of cardiovascular risk by examining patterns that conventional models frequently overlook. Using a generated dataset designed to mimic real patient data, we applied and assessed a range of machine learning algorithms, such as logistic regression, support vector machines, random forests, XGBoost, and neural networks on a generated dataset designed to replicate actual patient information. Accuracy, sensitivity, specificity, and AUC metrics were used to evaluate each model. Our results demonstrate that ensemble approaches and neural networks perform better than traditional models, especially when it comes to identifying high-risk instances. The study takes into account how these tools could be ethically incorporated into healthcare settings in addition to their predictive power. We talk about issues with ethical use, data quality, and generalizability. All things considered, this work bolsters the expanding importance of AI in improving the efficiency, preventiveness, and personalization of cardiovascular care.

KEYWORDS- Cardiovascular Diseases, Machine Learning, Artificial Intelligence, Risk Prediction, Personalized Medicine

I. INTRODUCTION AND CONTEXT

Figure 1: AI-Powered Cardiovascular Intelligence: The Future of Heart Health

A. Global Burden of Cardiovascular Diseases

About 17.9 million deaths a year, or almost 32% of all deaths worldwide, are attributed to cardiovascular diseases (CVDs), making them the leading cause of mortality worldwide [1][2]. These illnesses encompass a variety of conditions like heart failure, peripheral artery disease, coronary artery disease, and stroke (see Figure 1). A number of variables, including population aging, urbanization, poor dietary habits, sedentary lifestyles, and increased tobacco use, are responsible for the rising prevalence of CVDs, especially in low- and middle-income nations. Reducing the worldwide burden of CVD requires the early detection and treatment of those who are at high risk [3].

B. Limitations of Traditional Risk Prediction Models

For many years, traditional risk prediction algorithms such as the Framingham Risk Score and Pooled Cohort Equations have been used extensively to determine a person's chance of acquiring cardiovascular disease [4]. Nevertheless, these models depend on a small set of risk factors and are based on linear statistical connections [5]. Their applicability in a variety of clinical contexts is limited because they frequently overlook intricate, non-linear relationships and might not generalize well across various demographics and ethnicities [6]. These drawbacks highlight the need for risk prediction techniques that are more sophisticated and flexible.

C. Emergence of Artificial Intelligence in Cardiovascular Prediction

Machine learning (ML), a subset of artificial intelligence (AI), presents a viable substitute for conventional statistical techniques. Large volumes of diverse data may be processed by AI systems, which are also able to recognize complex patterns and continuously adjust to new information [7]. Medical imaging, wearable technology, genomic research, and electronic health records have all been analyzed using machine learning (ML) models in the field of cardiovascular medicine in order to predict adverse cardiac events, stratify patient risk, and customize treatment plans [8]. Numerous algorithms are used in these models, ranging from deep neural networks and intricate ensemble techniques to logistic regression and support vector machines. They are a powerful tool for revolutionizing the prevention and treatment of cardiovascular disease because of their ability to outperform conventional models in predicting accuracy [9].

D. Purpose and Scope of the Thesis

The use of AI-based predictive models for the management and prevention of cardiovascular diseases is examined in this thesis, with an emphasis on machine learning methodologies. In order to investigate how these models may be incorporated into healthcare systems for proactive patient care, it attempts to evaluate how well different machine learning algorithms perform on a simulated dataset that is based on actual cardiovascular data [10]. The work thus adds to the expanding corpus of information regarding the use of AI in clinical cardiology and identifies directions for further investigation and application [11].

II. ADVANCES IN AI AND MACHINE LEARNING FOR CARDIOVASCULAR RISK ASSESSMENT

A new area in predictive healthcare is represented by artificial intelligence, especially machine learning. ML models are capable of modeling non-linear correlations among numerous variables and are able to discover data patterns without explicit programming [12]. These models have shown excellent predictive performance for outcomes like myocardial infarction, stroke, and heart failure in cardiovascular medicine [13]. Support vector machines, decision trees, and ensemble models like random forests and XGBoost provide more complexity and performance than the basic approach of logistic regression. High-dimensional data, like that from imaging or ECG signals, is particularly well-suited for neural networks and deep learning architectures [14]. Additionally, wearable technology now gathers patient data in real time, such as physical activity and heart rate variability, enabling ongoing monitoring. For dynamic and individualized cardiovascular risk prediction, these data streams can be incorporated into machine learning algorithms [15].

III. RESEARCH DESIGN, DATASET, AND METHODOLOGICAL FRAMEWORK



Figure 2: Machine Learning Dashboard for Predicting Heart Disease: A New Era in Digital Cardiology

This study assesses how well different machine learning models predict the risk of CVD using a generated dataset that was inspired by the UCI Cleveland heart disease dataset (see Figure 2). 14 characteristics, including age, sex, kind of chest pain, cholesterol, resting blood pressure, fasting blood sugar, maximal heart rate, and exercise-induced angina, are included in the dataset, which consists of 303 entries [16][17][18].

One-hot encoding of categorical variables, normalization of numerical features, and median imputation were used in data preprocessing to handle missing values [19]. Five models—a neural network with one hidden layer, logistic regression, random forest, support vector machines with RBF kernels, and XGBoost—were trained and evaluated. 5-fold cross-validation assisted in optimizing hyperparameters and avoiding overfitting, and an 80/20 training-test split was employed [20]. A thorough evaluation of predictive performance was provided using evaluation criteria such as accuracy, sensitivity, specificity, area under the ROC curve (AUC), and F1-score [21].

IV. MODEL PERFORMANCE EVALUATION AND VISUALIZATION

Out of all the models, the neural network had the highest accuracy (90%) and was closely followed by XGBoost (87%) and the random forest (88%). The accuracies of SVM and logistic regression were 79% and 83%, respectively [22]. These findings were reflected in the sensitivity, specificity, and AUC values; the neural network performed the best overall, with its 92% specificity standing out in particular. In line with clinical knowledge, the random forest model's feature importance analysis revealed that the most significant predictors were age, cholesterol, and maximum heart rate [23].

The model results are compared and interpreted using the graphics below:

A. Comparison Of Ml Model Performance Metrics

This bar chart(see Figure 3) illustrates the comparative accuracy, sensitivity, and specificity of the five ML models, displaying the superior performance of the neural network and random forest models [24].

This line graph displays the AUC for each model (see Figure 4), indicating that the neural network achieves the highest discriminative power, followed closely by random forest and XGBoost [25].



Figure 3: Comparison of ML Model Performance Metrics



Figure 4: Area Under Curve (AUC) by Model



Figure 5: Feature Importance from Random Forest.

This bar chart ranks the most critical features for cardiovascular disease prediction according to the random forest model (see Figure 5). Age and cholesterol levels emerge as the top indicators [26].

Table 1: Summary of Model Performance Metrics

Model	Accuracy (%)	Sensitivity (%)	Specificity (%)	AUC
Logistic Regression	83	85	80	0.85
SVM	79	78	80	0.83
Random Forest	88	91	85	0.91
XGBoost	87	88	86	0.90
Neural Network	90	88	92	0.93

V. CLINICAL IMPLICATIONS, CHALLENGES, AND ETHICAL CONSIDERATIONS

There is a lot of promise for better cardiovascular outcomes when AI techniques are integrated into clinical settings. Early treatments can be facilitated by providing risk signals to doctors during consultations through the integration of predictive algorithms into electronic health records (EHRs) [27]. This may result in fewer severe cardiac episodes, better treatment regimens, and prompt lifestyle changes (see Table 1). AI tools can expand diagnostic and prognostic capabilities to primary care settings in areas with limited access to specialists, democratizing access to high-quality treatment [28].

Nonetheless, a number of issues must be resolved. Predictions from models based on homogeneous datasets run the risk of being biased since they may not generalize well to heterogeneous populations. Important ethical issues include patient data privacy, algorithmic decision transparency, and the requirement for informed consent [29]. Clinicians can better comprehend AI suggestions with the aid of explainability techniques like SHAP or LIME, which foster accountability and confidence. To control the creation, verification, and application of AI systems in healthcare, regulatory frameworks must change [30].

VI. RECOMMENDATIONS FOR FUTURE RESEARCH

The creation of predictive models based on various, multicenter datasets that represent populations around the world should be the top priority of future research. This will lower the possibility of bias and guarantee generalizability. Furthermore, to validate AI systems in everyday practice, prospective clinical research and real-world trials are required. Incorporating interpretable models or post-hoc explainability approaches such as SHAP and LIME are also necessary to address transparency and explainability [31].

For AI solutions to be scaled responsibly, cooperation between clinicians, data scientists, software developers, and legislators will be crucial. Fairness, informed consent, and patient data privacy are ethical issues that should continue to drive advancement. Furthermore, dynamic risk prediction can be supported by connecting AI systems with wearable technology and electronic health records, allowing for proactive and ongoing cardiovascular health management on a worldwide basis [32].

VII. CONCLUSION

This study demonstrates how artificial intelligence has the potential to revolutionize the diagnosis and treatment of cardiovascular illnesses. By identifying intricate patterns in patient data, machine learning models—particularly neural networks and ensemble approaches—perform better than conventional risk prediction tools. In order to promote early detection, individualized treatment, and real-time monitoring, these technologies can be included into clinical processes and wearable technology. This will advance proactive and data-driven cardiovascular healthcare globally.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. A. K. Bhatia, J. Ju, Z. Ziyang, N. Ahmed, A. Rohra, and M. Waqar, "Robust adaptive preview control design for autonomous carrier landing of F/A-18 aircraft," *Aircraft Eng. Aerosp. Technol.*, vol. 93, no. 4, pp. 642–650, 2021. Available from: https://doi.org/10.1108/AEAT-11-2020-0244
2. M. Waqar, I. Bhatti, and A. H. Khan, "AI-powered automation: Revolutionizing industrial processes and enhancing operational efficiency," *Rev. Intell. Artif. Med.*, vol. 15, no. 1, pp. 1151–1175, 2024. Available from: https://shorturl.at/A6lei
3. M. Waqar, A. H. Khan, and I. Bhatti, "Artificial intelligence in automated healthcare diagnostics: Transforming patient care," *Rev. Esp. Doc. Cient.*, vol. 19, no. 2, pp. 83–103, 2024. Available from: https://www.softude.com/blog/artificial-intelligence-in-healthcare-how-its-transforming-patient-care
4. M. Waqar, I. Bhatti, and A. H. Khan, "Leveraging machine learning algorithms for autonomous robotics in real-time operations," *Int. J. Adv. Eng. Technol. Innov.*, vol. 4, no. 1, pp. 1–24, 2024. Available from: https://shorturl.at/3SZAi
5. I. Bhatti, M. Waqar, and A. H. Khan, "The role of AI-driven automation in smart cities: Enhancing urban living through intelligent system," *Multidiscip. J. Instr.*, vol. 7, no. 1, pp. 101–114, 2024. Available from: https://shorturl.at/H7Buh
6. M. Arikhad, M. Waqar, A. H. Khan, and A. Sultana, "Transforming cardiovascular and neurological care with AI: A paradigm shift in medicine," *Rev. Intell. Artif. Med.*, vol. 15, no. 1, pp. 1264–1277, 2024. Available from: https://doi.org/10.1016/j.jacc.2024.05.003
7. H. Rafi, F. Ahmad, J. Anis, R. Khan, H. Rafiq, and M. Farhan, "Comparative effectiveness of agmatine and choline treatment in rats with cognitive impairment induced by AlCl3 and forced swim stress," *Curr. Clin. Pharmacol.*, vol. 15, no. 3, pp. 251–264, 2020. Available from: https://doi.org/10.2174/1574884714666191016152143
8. M. Farhan, H. Rafi, and H. Rafiq, "Behavioral evidence of neuropsychopharmacological effect of imipramine in animal model of unpredictable stress induced depression," *Int. J. Biol. Biotechnol.*, vol. 15, no. 22, pp. 213–221, 2018. Available from: https://shorturl.at/cVPMX
9. T. Ghulam, H. Rafi, A. Khan, K. Gul, and M. Z. Yusuf, "Impact of SARS-CoV-2 treatment on development of sensorineural hearing loss: Impact of SARS-CoV-2 treatment on SNHL," *Proc. Pak. Acad. Sci. B Life Environ. Sci.*, vol. 58, no. S, pp. 45–54, 2021. Available from: https://www.ppaspk.org/index.php/PPAS-B/article/view/469
10. H. Rafi, H. Rafiq, R. Khan, F. Ahmad, J. Anis, and M. Farhan, "Neuroethological study of ALCL3 and chronic forced swim stress induced memory and cognitive deficits in albino rats," *J. Neurobehav. Sci.*, vol. 6, no. 2, pp. 149–158, 2019. Available from: http://dx.doi.org/10.5455/JNBS.1558487053
11. H. Rafi and M. Farhan, "Dapoxetine: An innovative approach in therapeutic management in animal model of depression," *Pak. J. Pharm. Sci.*, vol. 2, no. 1, pp. 15–22, 2015. Available from: http://dx.doi.org/10.22200/pjpr.2016115-22
12. H. Rafiq, M. Farhan, H. Rafi, S. Rehman, M. Arshad, and S. Shakeel, "Inhibition of drug induced Parkinsonism by chronic supplementation of quercetin in haloperidol-treated wistars," *Pak. J. Pharm. Sci.*, vol. 35, pp. 1655–1662, 2022. Available from: https://doi.org/10.1016/s0028-3908(03)00101-1
13. H. Rafi, H. Rafiq, and M. Farhan, "Inhibition of NMDA receptors by agmatine is followed by GABA/glutamate balance in benzodiazepine withdrawal syndrome," *Beni-Suef Univ. J. Basic Appl. Sci.*, vol. 10, pp. 1–13, 2021. Available from: https://doi.org/10.1186/s43088-021-00125-8
14. H. Rafi, H. Rafiq, and M. Farhan, "Pharmacological profile of agmatine: An in-depth overview," *Neuropeptides*, vol. 2024, Art. no. 102429, 2024. Available from: https://doi.org/10.1016/j.npep.2024.102429
15. M. Farhan, H. Rafi, and H. Rafiq, "Dapoxetine treatment leads to attenuation of chronic unpredictable stress induced behavioral deficits in rats model of depression," *J. Pharm. Nutr. Sci.*, vol. 5, no. 4, pp. 222–228, 2015. Available from: https://doi.org/10.6000/1927-5951.2015.05.04.2
16. H. Rafi, H. Rafiq, and M. Farhan, "Antagonization of monoamine reuptake transporters by agmatine improves anxiolytic and locomotive behaviors commensurate with fluoxetine and methylphenidate," *Beni-Suef Univ. J. Basic Appl. Sci.*, vol. 10, pp. 1–14, 2021. Available from: https://doi.org/10.1186/s43088-021-00118-7
17. M. Farhan, H. Rafiq, H. Rafi, S. Rehman, and M. Arshad, "Quercetin impact against psychological disturbances induced by fat rich diet," *Pak. J. Pharm. Sci.*, vol. 35, no. 5, 2022. Available from: https://www.pjps.pk/uploads/pdfs/35/5/2-10511.pdf
18. H. Rafi, H. Rafiq, I. Hanif, R. Rizwan, and M. Farhan, "Chronic agmatine treatment modulates behavioral deficits induced by chronic unpredictable stress in wistar rats," *J. Pharm. Biol. Sci.*, vol. 6, no. 3, p. 80, 2018. Available from: https://pdf.ipinnovative.com/pdf/7845
19. S. Zuberi, H. Rafi, A. Hussain, and S. Hashmi, "Role of Nrf2 in myocardial infarction and ischemia-reperfusion injury," *Physiology*, vol. 38, no. S1, Art. no. 5734743, 2023. Available from: https://doi.org/10.1152/physiol.2023.38.S1.5734743
20. M. Farhan, H. Rafiq, H. Rafi, R. Ali, and S. Jahan, "Neuroprotective role of quercetin against neurotoxicity induced by lead acetate in male rats," *Int. J. Biol. Biotechnol.*, vol. 16, no. 2, pp. 291–297, 2019. Available from: https://shorturl.at/69cqO
21. H. Rafi, H. Rafiq, and M. Farhan, "Agmatine alleviates brain oxidative stress induced by sodium azide," unpublished, 2023. Available from: http://dx.doi.org/10.2174/0122127968308662240926114002
22. M. Farhan, H. Rafi, H. Rafiq, F. Siddiqui, R. Khan, and J. Anis, "Study of mental illness in rat model of sodium azide induced oxidative stress," *J. Pharm. Nutr. Sci.*, vol. 9, no. 4, pp. 213–221, 2019. Available from: https://doi.org/10.29169/1927-5951.2019.09.04.3
23. M. Farhan, H. Rafiq, and H. Rafi, "Prevalence of depression in animal model of high fat diet induced obesity," *J. Pharm. Nutr. Sci.*, vol. 5, no. 3, pp. 208–215, 2015. Available from: https://doi.org/10.6000/1927-5951.2015.05.03.6

24. S. R. P. Dandamudi, J. Sajja, and A. Khanna, "Leveraging artificial intelligence for data networking and cybersecurity in the United States," *Int. J. Innov. Res. Comput. Sci. Technol.*, vol. 13, no. 1, pp. 34–41, 2025. Available from: https://doi.org/10.55524/ijircst.2025.13.1.5
25. S. R. P. Dandamudi, J. Sajja, and A. Khanna, "Advancing cybersecurity and data networking through machine learning-driven prediction models," *Int. J. Innov. Res. Comput. Sci. Technol.*, vol. 13, no. 1, pp. 26–33, 2025. Available from: https://doi.org/10.55524/ijircst.2025.13.1.4
26. S. R. P. Dandamudi, J. Sajja, and A. Khanna, "Advancing cybersecurity and data networking through machine learning-driven prediction models," *Int. J. Innov. Res. Comput. Sci. Technol.*, vol. 13, no. 1, pp. 26–33, 2025. Available from: https://doi.org/10.55524/ijircst.2025.13.1.4
27. T. Mahmood, M. Asif, and Z. H. Raza, "Smart forestry: The role of AI and bioengineering in revolutionizing timber production and biodiversity protection," *Rev. Intell. Artif. Med.*, vol. 15, no. 1, pp. 1176–1202, 2024. Available from: https://shorturl.at/eXPFY
28. M. Asif, Z. H. Raza, and T. Mahmood, "Bioengineering applications in forestry: Enhancing growth, disease resistance, and climate resilience," *Rev. Esp. Doc. Cient.*, vol. 17, no. 1, pp. 62–88, 2023. Available from: https://shorturl.at/tIPc4
29. M. Arikhad, M. Waqar, A. H. Khan, and A. Sultana, "AI-driven innovations in cardiac and neurological healthcare: Redefining diagnosis and treatment," *Rev. Esp. Doc. Cient.*, vol. 19, no. 2, pp. 124–136, 2024. Available from: https://doi.org/10.53555/8xp0p349
30. M. Arikhad, M. Waqar, A. H. Khan, and A. Sultana, "The role of artificial intelligence in advancing heart and brain disease management," *Rev. Esp. Doc. Cient.*, vol. 19, no. 2, pp. 137–148, 2024. Available from: https://shorturl.at/QTSKR
31. M. Arikhad, A. H. Khan, M. Tariq, and A. A. Abrar, "AI-powered solutions for precision healthcare: Focusing on heart and brain disorders". Available from: https://doi.org/10.1101/2025.03.23.25324474
32. A. H. Khan, M. Arikhad, and M. Tariq, "Revolutionizing heart and brain healthcare with artificial intelligence: Challenges and opportunities". Available from: https://doi.org/10.1186/s12909-023-04698-z